Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

Lynne I. Wagner*, Fengmin Zhao, Paul E. Goss, Judith Anne W. Chapman, Lois E. Shepherd, Timothy J. Whelan, Bassam I. Mattar, Jose A. Bufill, William C. Schultz, Irving E. LaFrancis, Gauri G. Nagargoje, Radhakrishna Vemuri, Daniel A. Nikcevich, George W. Sledge, David Cella

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)'. Together they form a unique fingerprint.

Medicine & Life Sciences